131 related articles for article (PubMed ID: 361463)
21. Effects of chronic treatment with acarbose on glucose and lipid metabolism in obese diabetic Wistar rats.
Carrascosa JM; Molero JC; Fermín Y; Martínez C; Andrés A; Satrústegui J
Diabetes Obes Metab; 2001 Aug; 3(4):240-8. PubMed ID: 11520303
[TBL] [Abstract][Full Text] [Related]
22. The influence of a high-fibre diet on body weight, serum lipids and blood pressure in slightly overweight persons. A randomized, double-blind, placebo-controlled investigation with diet and fibre tablets (DumoVital).
Solum TT; Ryttig KR; Solum E; Larsen S
Int J Obes; 1987; 11 Suppl 1():67-71. PubMed ID: 3032827
[TBL] [Abstract][Full Text] [Related]
23. [Use of teronak for the treatment of obesity with and without diabetes mellitus].
Egart FM; Korotkova VD
Probl Endokrinol (Mosk); 1980; 26(2):16-20. PubMed ID: 7375451
[TBL] [Abstract][Full Text] [Related]
24. Hyperinsulinemia secondary to chronic administration of mazindol and d-amphetamine.
Sirtori C; Hurwitz A; Azarnoff DL
Am J Med Sci; 1971 Jun; 261(6):341-9. PubMed ID: 4948438
[No Abstract] [Full Text] [Related]
25. [Changes in meal patterns and endogenous chemical determinants related to food intake following intra-ventricle III infusion of mazindol].
Fujimoto K; Sakata T; Arase K; Tsutsui K; Fukushima M
Nihon Yakurigaku Zasshi; 1984 May; 83(5):425-32. PubMed ID: 6381262
[TBL] [Abstract][Full Text] [Related]
26. Double-blind trial of mazindol in overweight patients.
Heber KR
Med J Aust; 1975 Oct; 2(14):566-7. PubMed ID: 1105106
[TBL] [Abstract][Full Text] [Related]
27. [Effect of mazindol on free fatty acid metabolism in the brain of rats].
Mizobuchi M; Matsuoka N; Saito Y; Yoshida S; Kumagai A
Nihon Yakurigaku Zasshi; 1984 Jan; 83(1):33-7. PubMed ID: 6714850
[TBL] [Abstract][Full Text] [Related]
28. Three controlled trials of weight loss with phenylpropanolamine.
Altschuler S; Conte A; Sebok M; Marlin RL; Winick C
Int J Obes; 1982; 6(6):549-56. PubMed ID: 6761288
[TBL] [Abstract][Full Text] [Related]
29. A multi-centre trial of mazindol ('Teronac') in general practice in Ireland.
Evans ER; Wallace MG
Curr Med Res Opin; 1975; 3(3):132-7. PubMed ID: 1149481
[TBL] [Abstract][Full Text] [Related]
30. Effects of mazindol on carbohydrate and insulin metabolism in obesity.
Harrison LC; King-Roach AP; Sandy KC
Metabolism; 1975 Dec; 24(12):1353-65. PubMed ID: 1196130
[TBL] [Abstract][Full Text] [Related]
31. Letter: Drugs in obesity.
Jackson WP; Vinik AI
S Afr Med J; 1975 May; 49(20):803. PubMed ID: 1098170
[No Abstract] [Full Text] [Related]
32. Double-blind evaluation of mazindol in refractory obesity.
Smith RG; Innes JA; Munro JF
Br Med J; 1975 Aug; 3(5978):284. PubMed ID: 1097046
[No Abstract] [Full Text] [Related]
33. A multi-centre general practice trial of mazindol in the treatment of obesity.
Maclay WP; Wallace MG
Practitioner; 1977 Mar; 218(1305):431-4. PubMed ID: 322112
[No Abstract] [Full Text] [Related]
34. Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population.
Fagerberg B; Edwards S; Halmos T; Lopatynski J; Schuster H; Stender S; Stoa-Birketvedt G; Tonstad S; Halldórsdóttir S; Gause-Nilsson I
Diabetologia; 2005 Sep; 48(9):1716-25. PubMed ID: 16001233
[TBL] [Abstract][Full Text] [Related]
35. [Effect of mazindol on insulin and glucagon secretion in ventromedial hypothalamic obese rats].
Usami M; Seino Y; Nishi S; Nakahara H; Ikeda M; Matsukura S; Imura H
Nihon Yakurigaku Zasshi; 1985 Apr; 85(4):297-303. PubMed ID: 3891549
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of action of mazindol in preventing onset and development of obesity induced by gold thioglucose injection.
Kawano-Takahashi Y; Ohminaji H; Ubagai E; Okuda H
Int J Obes; 1984; 8(6):655-64. PubMed ID: 6442712
[TBL] [Abstract][Full Text] [Related]
37. Treatment of the obese diabetic. A comparative study of placebo, sulfonylurea and phenformin.
Abramson E; Arky RA
Metabolism; 1967 Mar; 16(3):204-12. PubMed ID: 5336062
[No Abstract] [Full Text] [Related]
38. No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity.
Visser M; Seidell JC; Koppeschaar HP; Smits P
Obes Res; 1994 Mar; 2(2):152-9. PubMed ID: 16353616
[TBL] [Abstract][Full Text] [Related]
39. Double-blind cross-over evaluation of mazindol in the treatment of obese hypertensive patients.
Miach PJ; Thomson W; Doyle AE; Louis WJ
Med J Aust; 1976 Sep; 2(10):378-80. PubMed ID: 792640
[TBL] [Abstract][Full Text] [Related]
40. Effects of aspartame in young persons during weight reduction.
Knopp RH; Brandt K; Arky RA
J Toxicol Environ Health; 1976 Nov; 2(2):417-28. PubMed ID: 796476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
